Dexo Laboratoire

Laboratoire Dexo was a French pharmaceutical company primarily focused on the development and commercialization of endocrinology and specialty healthcare products. The company established a strong presence in the French market with a portfolio centered on corticosteroid therapies, most notably dexamethasone and hydrocortisone. In 2016, the company was acquired by HRA Pharma, a move intended to expand HRA's footprint in the endocrinology and rare disease sectors. Today, the legacy products of Dexo are managed under the Perrigo umbrella following Perrigo's acquisition of HRA Pharma in 2022. The company was recognized for providing essential medicines for chronic hormonal conditions and acute inflammatory states.